Anzeige
Mehr »
Freitag, 05.12.2025 - Börsentäglich über 12.000 News
Das Timing könnte nicht besser sein - Durchbruchsjahr 2026 für Myriad
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A14156 | ISIN: GB00BYMT0J19 | Ticker-Symbol: LIA
Frankfurt
05.12.25 | 08:02
54,50 Euro
0,00 % 0,00
1-Jahres-Chart
LIVANOVA PLC Chart 1 Jahr
5-Tage-Chart
LIVANOVA PLC 5-Tage-Chart
RealtimeGeldBriefZeit
54,5055,0015:50
54,5055,0015:52

Aktuelle News zur LIVANOVA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiLivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting2
MiLivaNova PLC: LivaNova to Highlight Real-World Evidence from CORE-VNS Study and New Health Economics Analyses at American Epilepsy Society 2025 Annual Meeting218Eight scientific posters demonstrate significant seizure reduction and improved outcomes with VNS Therapy in patients with Drug-Resistant Epilepsy LivaNova PLC (Nasdaq: LIVN), a market-leading...
► Artikel lesen
DiLivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea1
DiLivaNova PLC: LivaNova Appoints Lucile Blaise as Global Head of Commercialization, Obstructive Sleep Apnea401LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, announced Lucile Blaise has joined the Company as Global Head of Commercialization, Obstructive Sleep Apnea (OSA), effective...
► Artikel lesen
25.11.LivaNova to Present at Piper Sandler Healthcare Conference in December1
25.11.LivaNova PLC: LivaNova to Present at Piper Sandler Healthcare Conference in December203LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that Alex Shvartsburg, Chief Financial Officer, will present a general business update during a fireside chat...
► Artikel lesen
24.11.LivaNova's VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services3
LIVANOVA Aktie jetzt für 0€ handeln
24.11.Höhere Medicare-Vergütung für LivaNova-Epilepsiebehandlung ab 20263
24.11.LivaNova PLC: LivaNova's VNS Therapy for Drug-Resistant Epilepsy Procedures Receives Increased Provider Reimbursement from U.S. Centers for Medicare & Medicaid Services220New patient implants assigned to New Technology Ambulatory Payment Classification 1580 - End-of-service procedures elevated to Level 5 APC - Effective Jan. 1, 2026, will improve economics for hospitals...
► Artikel lesen
13.11.LivaNova outlines plans for future growth at investor day event3
12.11.LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day2
12.11.LivaNova peilt bis 2030 hohes einstelliges Umsatzwachstum an15
12.11.LivaNova outlines 2030 targets with high-single-digit revenue growth1
12.11.LivaNova PLC: LivaNova Delivers Strategic Roadmap and Long-Range Financial Plan at Investor Day370Provides 2030 Targets for Revenue and EPS Growth LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today hosted its 2025 Investor Day and presented its comprehensive strategic...
► Artikel lesen
07.11.Needham reiterates Buy rating on Livanova stock ahead of Investor Day5
05.11.LivaNova raises 2025 revenue growth outlook to 10.5% amid strong cardiopulmonary expansion and Essenz China launch2
05.11.Stifel raises Livanova stock price target to $65 on strong Q3 results10
05.11.LivaNova PLC - 10-Q, Quarterly Report-
05.11.LivaNova beats Street in Q3, raises guidance again7
05.11.LivaNova PLC Non-GAAP EPS of $1.11 beats by $0.19, revenue of $357.8M beats by $15.08M1
Weiter >>
65 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1